MatchMedi
한국어

Options mapped

Phenylketonuria (PKU): options by country

Sourced options by country plus visit-prep questions for Phenylketonuria (PKU). Each line links to its regulator, HTA, or guideline source. This page maps options; it does not recommend or rank them.

Options mappedRare diseaseLast checked June 2026

What this page does

Maps options by country

It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.

What it does not do

Does not choose treatment

It does not rank treatments, recommend a choice, or decide clinical fit.

Where it comes from

Built on trusted sources

Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.

Information to gather before the next visit

  • Is the local access question about EU marketing authorisation or national reimbursement in France, Germany, or the UK?
  • For pegvaliase, is the person age 16 or older and is blood Phe inadequately controlled despite prior options as the source states?
  • For sapropterin or sepiapterin, has response been evaluated under the treating metabolic team's protocol?
  • Which Japanese package insert or MHLW reimbursement source confirms the current product and indication?

Trial-search terms to discuss

Phenylketonuria (PKU) clinical trial

Options by country

Treatments by country

Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.

European Union

  • sapropterin dihydrochloride (Kuvan); pegvaliase (Palynziq); sepiapterin (Sephience)[1]EMA authorisedPAH deficiency; BH4-responsive and sepiapterin-responsive contexts; Sapropterin as PKU/BH4-deficiency therapy and UK age-limited access; pegvaliase after inadequate Phe control despite prior management; sepiapterin in responsive PKU. · EMA authorisation does not by itself establish member-state reimbursement. NICE applies to England/Wales-type NHS contexts and is age/continuation constrained. HAS and G-BA are national HTA/reimbursement or benefit-assessment sources, not clinical eligibility determinations for an individual. Confidence/conflicts: High for EMA/NICE/HAS/G-BA sourced jurisdiction claims; no direct France/Germany Sephience reimbursement source captured yet.
  • sapropterin dihydrochloride (Kuvan); pegvaliase (Palynziq); sepiapterin (Sephience)[1]EMA authorisedPAH deficiency; BH4-responsive and sepiapterin-responsive contexts; Sapropterin as PKU/BH4-deficiency therapy and UK age-limited access; pegvaliase after inadequate Phe control despite prior management; sepiapterin in responsive PKU. · EMA authorisation does not by itself establish member-state reimbursement. NICE applies to England/Wales-type NHS contexts and is age/continuation constrained. HAS and G-BA are national HTA/reimbursement or benefit-assessment sources, not clinical eligibility determinations for an individual. Confidence/conflicts: High for EMA/NICE/HAS/G-BA sourced jurisdiction claims; no direct France/Germany Sephience reimbursement source captured yet.

Japan

  • sapropterin dihydrochloride (Biopten / Kuvan context); sepiapterin (Sephience)[2]PMDA-approved (Japan)PAH deficiency; BH4-responsive and sepiapterin-responsive contexts; BH4-responsive PKU for sapropterin; adult and pediatric PKU for sepiapterin per manufacturer approval announcement. · These Japan claims are manufacturer/regulatory-announcement sourced rather than direct PMDA label text. Current reimbursement, product name, and package-insert details need direct PMDA/MHLW verification. Confidence/conflicts: Medium because direct PMDA/MHLW labels were not fetched; no conflict identified.
  • sapropterin dihydrochloride (Biopten / Kuvan context); sepiapterin (Sephience)[2]PMDA-approved (Japan)PAH deficiency; BH4-responsive and sepiapterin-responsive contexts; BH4-responsive PKU for sapropterin; adult and pediatric PKU for sepiapterin per manufacturer approval announcement. · These Japan claims are manufacturer/regulatory-announcement sourced rather than direct PMDA label text. Current reimbursement, product name, and package-insert details need direct PMDA/MHLW verification. Confidence/conflicts: Medium because direct PMDA/MHLW labels were not fetched; no conflict identified.

Australia

  • pegvaliase (Palynziq)[3]TGA-registered (Australia)PAH deficiency; not limited to BH4-responsive disease in the cited TGA pegvaliase indication; PKU age 16 years and older with inadequate blood phenylalanine control despite prior management in Australia. · The AusPAR verifies registration and indication but not public subsidy. The TGA document records Black Triangle Scheme conditions and advisory discussion emphasizing careful monitoring because of adverse events. Confidence/conflicts: High for Australian TGA-approved indication; reimbursement status remains source-pending. No conflict identified.
  • pegvaliase (Palynziq)[3]TGA-registered (Australia)PAH deficiency; not limited to BH4-responsive disease in the cited TGA pegvaliase indication; PKU age 16 years and older with inadequate blood phenylalanine control despite prior management in Australia. · The AusPAR verifies registration and indication but not public subsidy. The TGA document records Black Triangle Scheme conditions and advisory discussion emphasizing careful monitoring because of adverse events. Confidence/conflicts: High for Australian TGA-approved indication; reimbursement status remains source-pending. No conflict identified.
  • phenylalanine-restricted diet, special low-protein foods, PKU formula/medical nutrition support[4]Standard option (per Australian Government Department of Health, Disability and Ageing)PAH deficiency / PKU; DHPR deficiency and HPA also included in the Australian IEM form source; lifelong dietary/specialised-food support and newborn/ongoing PKU nutrition management in Australia. · The IEM program is financial support for specialised food, not a drug approval. Reapplication intervals and metabolic-specialist involvement apply; individual nutrition targets are outside this catalog entry. Confidence/conflicts: High for Australian dietary-support pathway and PKU nutrition framing; no source conflict identified.
  • sepiapterin (Sephience)[5]TGA-registered (Australia)PAH deficiency; TGA registration page does not restrict to a named genotype; adult and paediatric PKU with HPA in Australia. · Registration and risk-management conditions are verified, but PBS subsidy or individual access criteria were not established. The advisory committee proposed wording included proven responsiveness, while the final TGA indication shown in the source is broader. Confidence/conflicts: High for Australian registration; medium for payer/access pathway, which is not established by these sources. Advisory wording and final indication differ in specificity, recorded above. Availability/reimbursement outside the approving regulator not established.

Thailand

  • sapropterin / tetrahydrobiopterin (BH4)[6]EMA authorisedelevated phenylalanine; PAH mutation, normal pterins/DHPR, or BH4 loading test criteria as listed in Thai access form; Thai national-list controlled-use/preauthorization context for sapropterin in PKU after dietary management and BH4 responsiveness criteria. · This is Thai-language access/form content and requires human review before patient-facing reuse. It is not a full product label and does not establish that every PKU patient is eligible; it documents a controlled-use pathway and criteria fields used for approval/continuation. Confidence/conflicts: Medium-high for existence of a Thai controlled-use pathway and form criteria; no conflict identified, but Thai-language clinical/access content needs human review and product-label details remain a gap. Primary source is in Thai. English summary pending human review — confirm exact wording with your care team. Availability/reimbursement outside the approving regulator not established.

Canada

  • pegvaliase (Palynziq)[7]Health Canada approvedPAH deficiency; inadequate phenylalanine control context; PKU age 16 years and older with blood Phe greater than 600 micromol/L despite dietary management in Canada. · The product monograph includes systemic hypersensitivity/anaphylaxis warnings and supervised initial administration requirements. CADTH reimbursement recommendation is conditional and does not guarantee provincial listing or individual access. Confidence/conflicts: High for Canadian label and CADTH conditional reimbursement recommendation; provincial implementation remains source-pending. No conflict identified.
  • pegvaliase (Palynziq)[7]Health Canada approvedPAH deficiency; inadequate phenylalanine control context; PKU age 16 years and older with blood Phe greater than 600 micromol/L despite dietary management in Canada. · The product monograph includes systemic hypersensitivity/anaphylaxis warnings and supervised initial administration requirements. CADTH reimbursement recommendation is conditional and does not guarantee provincial listing or individual access. Confidence/conflicts: High for Canadian label and CADTH conditional reimbursement recommendation; provincial implementation remains source-pending. No conflict identified.
  • sapropterin dihydrochloride (Kuvan)[8]Health Canada approvedPAH deficiency with BH4-responsive phenotype; BH4-responsive PKU with Phe-restricted diet in Canada. · Health Canada label does not establish provincial reimbursement or metabolic-clinic response criteria. The monograph states treatment should be directed by physicians knowledgeable in PKU management and that blood Phe levels should be monitored. Confidence/conflicts: High for Canadian label and marketed status; reimbursement status remains source-pending. No conflict identified.
  • sepiapterin for oral suspension (Sephience)[9]Health Canada approvedPAH deficiency; sepiapterin-responsive phenotype; sepiapterin-responsive PKU in patients 1 month and older in Canada, with Phe-restricted diet. · Health Canada notes long-term safety data are limited, especially for young pediatric patients, and that blood Phe levels and dietary Phe intake should be monitored. Reimbursement review/implementation was not established by the fetched Health Canada sources. Confidence/conflicts: High for Canadian approval, indication, and marketed status; reimbursement remains source-pending. No conflict identified.

Sources

  1. European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
  2. BioMarin Pharmaceutical — manufacturer regulatory approval announcement · manufacturer regulatory approval announcement
  3. Therapeutic Goods Administration (TGA) — Australian Public Assessment Report · Australian Public Assessment Report
  4. Australian Government Department of Health, Disability and Ageing — public health support program page · public health support program page
  5. Therapeutic Goods Administration (TGA) — prescription medicine registration page · prescription medicine registration page
  6. Thai National Drug Information / Thai FDA-MOPH — national-list controlled-use notice · national-list controlled-use notice
  7. Health Canada Drug Product Database — drug product database record · drug product database record
  8. Health Canada Drug Product Database — drug product database record · drug product database record
  9. Health Canada Drug Product Database — drug product database record · drug product database record

This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked 2026-06-12.

Beyond approved care

In clinical trials & emerging options

Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.

In clinical trials

  • sepiapterin / PTC923; pegvaliase (Palynziq); sapropterin (Kuvan)Clinical trial · NCT05099640Clinical trialTrial only (registry)European Union · PAH deficiency; trial-specific age/response criteria; PTC923/sepiapterin phase 3 PKU study; pegvaliase adolescent ages 12-17 study; Kuvan in PKU patients less than 4 years old with Phe-restricted diet. · Trial status includes completed and active-not-recruiting records. Site-country presence does not mean a treatment is currently accessible outside trial/extension or approved locally. Sepiapterin is separately authorised in U.S./EU sources above, but the registry cell is trial-specific. Confidence/conflicts: High for registry geography/status; routine access must be supported by separate regulator or payer sources. ClinicalTrials.gov — clinical-trial registry
  • sepiapterin / PTC923; pegvaliase (Palynziq); sapropterin (Kuvan)Clinical trial · NCT05099640Clinical trialTrial only (registry)European Union · PAH deficiency; trial-specific age/response criteria; PTC923/sepiapterin phase 3 PKU study; pegvaliase adolescent ages 12-17 study; Kuvan in PKU patients less than 4 years old with Phe-restricted diet. · Trial status includes completed and active-not-recruiting records. Site-country presence does not mean a treatment is currently accessible outside trial/extension or approved locally. Sepiapterin is separately authorised in U.S./EU sources above, but the registry cell is trial-specific. Confidence/conflicts: High for registry geography/status; routine access must be supported by separate regulator or payer sources. ClinicalTrials.gov — clinical-trial registry
  • sepiapterin / PTC923; pegvaliase (Palynziq); sapropterin (Kuvan)Clinical trial · NCT05099640Clinical trialTrial only (registry)European Union · PAH deficiency; trial-specific age/response criteria; PTC923/sepiapterin phase 3 PKU study; pegvaliase adolescent ages 12-17 study; Kuvan in PKU patients less than 4 years old with Phe-restricted diet. · Trial status includes completed and active-not-recruiting records. Site-country presence does not mean a treatment is currently accessible outside trial/extension or approved locally. Sepiapterin is separately authorised in U.S./EU sources above, but the registry cell is trial-specific. Confidence/conflicts: High for registry geography/status; routine access must be supported by separate regulator or payer sources. ClinicalTrials.gov — clinical-trial registry
  • GS1168 injection; NGGT002 AAV gene therapy; Palynziq nutritional-impact studyClinical trial · NCT07318909Clinical trialTrial only (registry)China · PAH deficiency; classic PKU or adult PKU in gene-therapy protocols; Adult PKU early-phase gene/injection study in China; adult classic PKU AAV gene therapy study in the United States; U.S. observational/interventional Palynziq nutritional-impact context. · GS1168 and NGGT002 are investigational. The China record was not yet recruiting at last registry update. Palynziq routine approval is separately handled in the U.S. label finding. Confidence/conflicts: High for registry cells; low for routine China/U.S. access to investigational products outside trials. ClinicalTrials.gov — clinical-trial registry
  • GS1168 injection; NGGT002 AAV gene therapy; Palynziq nutritional-impact studyClinical trial · NCT07318909Clinical trialTrial only (registry)China · PAH deficiency; classic PKU or adult PKU in gene-therapy protocols; Adult PKU early-phase gene/injection study in China; adult classic PKU AAV gene therapy study in the United States; U.S. observational/interventional Palynziq nutritional-impact context. · GS1168 and NGGT002 are investigational. The China record was not yet recruiting at last registry update. Palynziq routine approval is separately handled in the U.S. label finding. Confidence/conflicts: High for registry cells; low for routine China/U.S. access to investigational products outside trials. ClinicalTrials.gov — clinical-trial registry
  • GS1168 injection; NGGT002 AAV gene therapy; Palynziq nutritional-impact studyClinical trial · NCT07318909Clinical trialTrial only (registry)China · PAH deficiency; classic PKU or adult PKU in gene-therapy protocols; Adult PKU early-phase gene/injection study in China; adult classic PKU AAV gene therapy study in the United States; U.S. observational/interventional Palynziq nutritional-impact context. · GS1168 and NGGT002 are investigational. The China record was not yet recruiting at last registry update. Palynziq routine approval is separately handled in the U.S. label finding. Confidence/conflicts: High for registry cells; low for routine China/U.S. access to investigational products outside trials. ClinicalTrials.gov — clinical-trial registry

A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked 2026-06-12.